Fintel on MSN11h
Wedbush Downgrades Sutro Biopharma (STRO)Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...
John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...
BofA downgraded Sutro Biopharma (STRO) to Underperform from Buy with a price target of $1, down from $11, following the company’s announcement ...
MoonLake, a clinical-stage biopharma company developing immunology therapeutics, was created by an April 2022 merger with ...
As we reflect on five years of COVID-19, it’s clear that the impacts are still unfolding. The life sciences—and we as ...
HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or ...
StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research ...
Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith ...
Benitec Biopharma Inc. (NASDAQ:BNTC – Get Free Report) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $11.29 and traded as high as $13.45.
Zacks Investment Research on MSN1d
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue EstimatesSutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to earnings of $0.42 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback